coagulation factor viii

Coagulation factor VIII is an essential blood-clotting protein that serves as a critical cofactor in the intrinsic pathway of the coagulation cascade. It works by binding to activated factor IX (FIXa) to form the 'tenase' complex, which significantly accelerates the activation of factor X to factor Xa, leading to thrombin generation and fibrin clot formation. In patients with hemophilia A, a deficiency or defect in factor VIII results in impaired hemostasis and a severe bleeding tendency. Replacement therapy with coagulation factor VIII—available as either human plasma-derived concentrates or recombinant proteins—is the standard treatment for managing and preventing bleeding episodes. The product developed by Chengdu Rongsheng Pharmaceutical is a human-derived concentrate currently undergoing post-marketing Phase IV evaluation in China to assess its hemostatic efficacy and safety for on-demand treatment in hemophilia A patients.